Dr. Paul Harari is chairman of the Department of Human Oncology, principal investigator for the Wisconsin H&N SPORE Grant and member of the UW Carbone Cancer Center Senior Leadership Council. His clinical and laboratory research is focused on improving treatment outcomes for patients with head and neck cancer.
Radiation Oncologist
Rad onc physician
Michael Bassetti, MD, PhD
Dr. Bassetti is an associate professor in the Department of Human Oncology with a clinical focus on gastrointestinal cancers and research interests in MRI-guided radiation and immunotherapy. He has been developing the use of real-time MRI-guided radiation to reduce toxicity, maximize local control and improve patient outcomes. Additionally, he is involved in combining immunotherapies with anatomically targeted high-dose radiotherapy to improve the antigen specific T cell response.
Adam Burr, MD, PhD
Bethany Anderson, MD
Dr. Anderson’s research investigates ways to improve cancer control and reduce side effects of treatment for breast and gynecologic cancer. This includes using advanced imaging and radiation delivery techniques to more precisely identify and treat cancerous areas. I also study shorter treatment courses.
Zachary Morris, MD, PhD
The Morris Lab is focused on using preclinical and translational research approaches to study the mechanisms whereby radiation may impact the anti-tumor response to immunotherapies. Their primary objective is to determine whether and how radiation may optimally be employed to simultaneously modulate the tumor immune microenvironment and to increase the susceptibility of tumor cells to immune response. They seek to test these approaches in early phase clinical studies where they may be further refined with the ultimate aim of improving survival and achieving cures in patients with metastatic cancers.
Gregory Cooley, MD
Dr. Cooley is a clinical associate professor in the Department of Human Oncology (DHO). The DHO is one of the few centers in the region offering both low-dose-rate and high-dose-rate prostate brachytherapy. Two decades ago, prostate brachytherapy showed superior PSA control rates. With further advances in dosing, fractionation and MRI-based planning, results are even better.
Andrew Baschnagel, MD
Dr. Baschnagel is actively involved in translational and clinical research. I work closely with basic scientists, physicists and clinicians with the goal of fostering new ideas and translating research findings into the clinic. He has experience studying combinations of radiation and novel radiosensitizers and biomarkers of treatment response in patients and in preclinical models. His current work focuses on improving treatment of non-small cell lung cancer with a focus on brain metastases. He is actively involved at the regional and national level, and I am site PI for multiple national clinical studies here at UW.
Randall Kimple, MD, PhD, FASTRO
Dr. Kimple’s lab has established one of the largest tissue repositories of head and neck cancer patient-derived xenografts and have helped define best practices for the establishment, passage, and use of these valuable resources. Patient derived xenografts are established in mice directly from patient biopsies and are thought to better represent the biology of their human source than model cell lines grown in plastic tissue culture plates.